Literature DB >> 14694885

[Psychiatrists and the pharmaceutical industry].

H Helmchen1.   

Abstract

Relationships between psychiatrists and the pharmaceutical industry have increased in frequency and intensity, both on the individual level and particularly on the institutional level. They extend from necessary and desirable cooperation to questionable practices and to unacceptable misconduct. Especially the latter has provoked a lively discussion and has initiated recommendations as well as guidelines. Their aim is to safeguard the integrity of physicians as well as the industry and to avoid endangering the relationship between the physician and the patient. They will do this by establishing clear norms, unequivocal documentation, and disclosure of relevant relationships in order to build up more mutual trust including that of the public. Based on a detailed review of the literature, 27 recommendations are put forward for discussion. Psychiatric associations should develop explicit guidelines for the relationships between psychiatrists and the pharmaceutical industry.

Entities:  

Mesh:

Year:  2003        PMID: 14694885     DOI: 10.1007/s00115-003-1620-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  76 in total

1.  Interactions between physicians and the health care technology industry.

Authors:  R M Tenery
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Science and business. Conflicts of interest--moving beyond disclosure.

Authors:  T R Cech; J S Leonard
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

3.  A national survey of policies on disclosure of conflicts of interest in biomedical research.

Authors:  S V McCrary; C B Anderson; J Jakovljevic; T Khan; L B McCullough; N P Wray; B A Brody
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

4.  Policies on faculty conflicts of interest at US universities.

Authors:  M K Cho; R Shohara; A Schissel; D Rennie
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

5.  Ethics and industry-sponsored research.

Authors:  Joseph L Pater; Wendy Parulekar; Christopher O'Callagham; Lois Shepherd; Elizabeth Eisenhouer; Lesley Seymour; Dongsheng Tu; Keyue Ding
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

6.  Ethics and industry-sponsored research.

Authors:  Barry Koehler
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

7.  [Aims and background of the anticorruption law].

Authors:  H Mühlhausen
Journal:  Wien Med Wochenschr       Date:  2002

8.  Clinical trials in primary care: targeted payments for trials might help improve recruitment and quality.

Authors:  R Foy; J Parry; B McAvoy
Journal:  BMJ       Date:  1998-10-31

9.  Unpublished research from a medical specialty meeting: why investigators fail to publish.

Authors:  E J Weber; M L Callaham; R L Wears; C Barton; G Young
Journal:  JAMA       Date:  1998-07-15       Impact factor: 56.272

10.  The accuracy of drug information from pharmaceutical sales representatives.

Authors:  M G Ziegler; P Lew; B C Singer
Journal:  JAMA       Date:  1995-04-26       Impact factor: 56.272

View more
  1 in total

1.  What is the impact of financial conflicts of interest on the development of psychiatry?

Authors:  Andrés Heerlein
Journal:  World Psychiatry       Date:  2007-02       Impact factor: 49.548

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.